Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SAB Biotherapeutics ( (SABS) ) has issued an announcement.
On September 26, 2025, SAB Biotherapeutics held a special meeting where stockholders approved amendments to the company’s 2021 Omnibus Equity Incentive Plan, significantly increasing the number of shares available for participants. Additionally, stockholders approved the potential issuance of shares exceeding 19.99% of the company’s outstanding stock upon conversion of Series B Convertible Preferred Stock, which may be considered a ‘change of control’ under Nasdaq rules.
The most recent analyst rating on (SABS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
Spark’s Take on SABS Stock
According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.
SAB Biotherapeutics’ overall stock score is primarily influenced by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis provides a neutral outlook with no strong momentum, while the valuation is unattractive due to a negative P/E ratio and no dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on SABS stock, click here.
More about SAB Biotherapeutics
SAB Biotherapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing advanced immunotherapies. The company specializes in producing human antibodies for infectious diseases, immune system disorders, and other health conditions.
Average Trading Volume: 1,488,499
Technical Sentiment Signal: Sell
Current Market Cap: $22.49M
For detailed information about SABS stock, go to TipRanks’ Stock Analysis page.